XML 21 R10.htm IDEA: XBRL DOCUMENT v3.25.3
Historical Loss And LAE Development
9 Months Ended
Sep. 30, 2025
Historical Loss And L A E Development Disclosure [Abstract]  
Historical Loss And LAE Development

3. HISTORICAL LOSS AND LAE DEVELOPMENT

The following table is a reconciliation of our unpaid losses and settlement expenses (LAE) for the first nine months of 2025 and 2024:

For the Nine Months

Ended September 30,

(in thousands)

 

2025

 

2024

Unpaid losses and LAE at beginning of year

Gross

$

2,693,470

$

2,446,025

Ceded

(755,425)

(757,349)

Net

$

1,938,045

$

1,688,676

Increase (decrease) in incurred losses and LAE

Current accident year

$

623,926

$

599,183

Prior accident years

(74,112)

(85,442)

Total incurred

$

549,814

$

513,741

Loss and LAE payments for claims incurred

Current accident year

$

(74,868)

$

(76,148)

Prior accident years

(309,548)

(273,868)

Total paid

$

(384,416)

$

(350,016)

Net unpaid losses and LAE at September 30,

$

2,103,443

$

1,852,401

Unpaid losses and LAE at September 30,

Gross

$

2,873,054

$

2,611,941

Ceded

(769,611)

(759,540)

Net

$

2,103,443

$

1,852,401

For the first nine months of 2025, incurred losses and LAE included $74 million of favorable development on prior years’ loss reserves, largely from accident years 2019 through 2022 and 2024. Commercial excess liability, marine, surety, commercial property, general liability and our mortgage reinsurance program were drivers of the favorable development. While no products experienced significant adverse development, auto liability exposures developed adversely for some products, most notably in commercial transportation.

For the first nine months of 2024, incurred losses and LAE included $85 million of favorable development on prior years’ loss reserves, largely from accident years 2016, 2017, 2019, 2020, 2022 and 2023. Marine, surety, commercial property, commercial excess liability, general liability, professional services, executive products and personal umbrella were drivers of the favorable development. No products experienced significant adverse development.